We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System Treats Chronic Pain

By HospiMedica International staff writers
Posted on 20 Dec 2022
Print article
Image: Abbott`s Eterna spinal cord stimulation system is FDA-approved for the treatment of chronic pain (Photo courtesy of Pexels)
Image: Abbott`s Eterna spinal cord stimulation system is FDA-approved for the treatment of chronic pain (Photo courtesy of Pexels)

More than 50 million people in the U.S. suffer from chronic pain. According to the U.S. Pain Foundation, chronic pain is the leading cause of people going to the doctor and costs the nation approximately USD 635 billion each year in healthcare, disability and lost productivity costs. Spinal cord stimulation (SCS), also known as neurostimulation, has been recommended by doctors for more than 50 years to help people manage chronic pain and improve their quality of life. Devices used for SCS consist of thin wires placed between the spinal cord and the vertebrae and a small implant placed under the skin in the lower back that helps disrupt pain signals before they can reach the brain. Now, a new neuromodulation device provides an optimized experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable SCS systems.

Abbott’s (Lake Forest, IL, USA) Eterna SCS system is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. Abbott has developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a smaller implant for comfort while reducing the need to charge the device daily or weekly. Eterna needs to be recharged less than five times a year under normal use, making it the lowest recharge burden platform on the market.

The Eterna SCS system features Abbott's proprietary BurstDR stimulation, which mimics natural firing patterns found in the brain to deliver superior pain relief. BurstDR stimulation is preferred to traditional "tingling" tonic stimulation by 87% of patients. Paired with Abbott's new Xtend energy technology, Eterna optimizes the patient charging experience, requiring as few as five recharges per year under standard use from a wireless charger. Eterna uses Abbott's TotalScan MRI technology, which allows for full-body MRI scans – a critical need of chronic pain patients who require accessibility to improved diagnostics and healthcare. The Eterna SCS system can adapt to future innovations without replacing the implant. Abbott's patient-focused mobile app supports real-time battery life and charging status updates of the Eterna SCS system on a personal or Abbott-provided Apple device. The U.S. Food and Drug Administration (FDA) has approved the Eterna SCS system for the treatment of chronic pain.

"Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience – all key features when selecting the best overall system," said Pedro Malha, vice president, neuromodulation, Abbott.

Related Links:
Abbott

New
Platinum Supplier
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Smart nCPAP Device
SVAAS nCPAP
New
Double-Door Pass-Through Autoclave
150L - 700L Double-Door / Pass-Through
New
Surgical Light
HyLED 600 Series

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The new biomaterial heals tissues from the inside out (Photo courtesy of UC San Diego)

Groundbreaking Biomaterial Injected Intravenously Repairs Cells and Tissue Damaged by Heart Attack and TBI

Following a heart attack, there is development of scar tissue, which affects muscle function and can result in congestive heart failure. However, there is still no established treatment available for repairing... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.